COVID-19 in patients with autoimmune diseases : characteristics and outcomes in a multinational network of cohorts across three countries
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology..
OBJECTIVE: Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza.
METHODS: A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization.
RESULTS: We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%).
CONCLUSION: Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 60(2021), SI vom: 09. Okt., Seite SI37-SI50 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 16.02.2024 published: Print UpdateOf: medRxiv. 2020 Nov 27;:. - PMID 33269355 Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/keab250 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322817676 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322817676 | ||
| 003 | DE-627 | ||
| 005 | 20240216232128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keab250 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1295.xml |
| 035 | |a (DE-627)NLM322817676 | ||
| 035 | |a (NLM)33725121 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tan, Eng Hooi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 in patients with autoimmune diseases |b characteristics and outcomes in a multinational network of cohorts across three countries |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a UpdateOf: medRxiv. 2020 Nov 27;:. - PMID 33269355 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. | ||
| 520 | |a OBJECTIVE: Patients with autoimmune diseases were advised to shield to avoid coronavirus disease 2019 (COVID-19), but information on their prognosis is lacking. We characterized 30-day outcomes and mortality after hospitalization with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza | ||
| 520 | |a METHODS: A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center [USA, Optum (USA), Department of Veterans Affairs (USA), Information System for Research in Primary Care-Hospitalization Linked Data (Spain) and claims data from IQVIA Open Claims (USA) and Health Insurance and Review Assessment (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalized between January and June 2020 with COVID-19, and similar patients hospitalized with influenza in 2017-18 were included. Outcomes were death and complications within 30 days of hospitalization | ||
| 520 | |a RESULTS: We studied 133 589 patients diagnosed and 48 418 hospitalized with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45.5-93.2%), chronic kidney disease (14.0-52.7%) and heart disease (29.0-83.8%) was higher in hospitalized vs diagnosed patients with COVID-19. Compared with 70 660 hospitalized with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2-4.3% vs 6.32-24.6%) | ||
| 520 | |a CONCLUSION: Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Observational Health Data Sciences and Informatics (OHDSI) | |
| 650 | 4 | |a Observational Medical Outcomes Partnership (OMOP) | |
| 650 | 4 | |a autoimmune condition | |
| 650 | 4 | |a hospitalization | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a open science | |
| 700 | 1 | |a Sena, Anthony G |e verfasserin |4 aut | |
| 700 | 1 | |a Prats-Uribe, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a You, Seng Chan |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Waheed-Ul-Rahman |e verfasserin |4 aut | |
| 700 | 1 | |a Kostka, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Reich, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Duvall, Scott L |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, Kristine E |e verfasserin |4 aut | |
| 700 | 1 | |a Matheny, Michael E |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte-Salles, Talita |e verfasserin |4 aut | |
| 700 | 1 | |a Bertolin, Sergio Fernandez |e verfasserin |4 aut | |
| 700 | 1 | |a Hripcsak, George |e verfasserin |4 aut | |
| 700 | 1 | |a Natarajan, Karthik |e verfasserin |4 aut | |
| 700 | 1 | |a Falconer, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Spotnitz, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Ostropolets, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Blacketer, Clair |e verfasserin |4 aut | |
| 700 | 1 | |a Alshammari, Thamir M |e verfasserin |4 aut | |
| 700 | 1 | |a Alghoul, Heba |e verfasserin |4 aut | |
| 700 | 1 | |a Alser, Osaid |e verfasserin |4 aut | |
| 700 | 1 | |a Lane, Jennifer C E |e verfasserin |4 aut | |
| 700 | 1 | |a Dawoud, Dalia M |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Karishma |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Areia, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Golozar, Asieh |e verfasserin |4 aut | |
| 700 | 1 | |a Recalde, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Casajust, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Jonnagaddala, Jitendra |e verfasserin |4 aut | |
| 700 | 1 | |a Subbian, Vignesh |e verfasserin |4 aut | |
| 700 | 1 | |a Vizcaya, David |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Lana Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Nyberg, Fredrik |e verfasserin |4 aut | |
| 700 | 1 | |a Morales, Daniel R |e verfasserin |4 aut | |
| 700 | 1 | |a Posada, Jose D |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Nigam H |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Mengchun |e verfasserin |4 aut | |
| 700 | 1 | |a Vivekanantham, Arani |e verfasserin |4 aut | |
| 700 | 1 | |a Abend, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Minty, Evan P |e verfasserin |4 aut | |
| 700 | 1 | |a Suchard, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Rijnbeek, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Ryan, Patrick B |e verfasserin |4 aut | |
| 700 | 1 | |a Prieto-Alhambra, Daniel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 60(2021), SI vom: 09. Okt., Seite SI37-SI50 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g number:SI |g day:09 |g month:10 |g pages:SI37-SI50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keab250 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 2021 |e SI |b 09 |c 10 |h SI37-SI50 | ||